Skip to main content
. Author manuscript; available in PMC: 2015 Jan 10.
Published in final edited form as: J Control Release. 2013 Nov 2;173:10.1016/j.jconrel.2013.10.031. doi: 10.1016/j.jconrel.2013.10.031

Table 1.

Summary of different formulations and therapeutic protocols and their abbreviations

Abbreviation Formulation Therapeutic protocol
nChain αvβ3 integrin-targeting nChain nanochains no radiofrequency (RF) application
nChain/RF αvβ3 integrin-targeting nChain nanochains 45 min after injection of the formulation, the RF field was applied for 60 min
NT-nChain non-targeted nanochains no RF application
Lip αvβ3 integrin-targeting 35-nm liposome no RF application
Lip/RF αvβ3 integrin-targeting 35-nm liposome 45 min after injection of the formulation, the RF field was applied for 60 min
NT-Lip non-targeted 35-nm liposome no RF application
DOX/RF free doxorubicin 45 min after injection of the formulation, the RF field was applied for 60 min
HHS Vulnerability Disclosure